{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:04:47Z","timestamp":1759017887040,"version":"3.44.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clinthera.2018.06.010","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T09:14:54Z","timestamp":1532337294000},"page":"1357-1365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects"],"prefix":"10.1016","volume":"40","author":[{"given":"Eric R.","family":"Kinzler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Pantaleon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.06.010_bib0001","unstructured":"Center for Behavioral Health Statistics and Quality. Behavioral Health Trends in the United States: Results from the\n2014 National Survey on Drug Use and Health. HHS Publication No. SMA 15-4927, NSDUH Series H-50. Available at: http:\/\/www.samhsa.gov\/data\/2015;accessed 22 May 2018"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0002","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jsr.2012.08.009","article-title":"Prescription drug overdoses: a review","volume":"43","author":"Paulozzi","year":"2012","journal-title":"Journal of safety research"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0003","unstructured":"Centers for Disease Control and Prevention. Prescription overdose data 2017. https:\/\/www.cdc.gov\/drugoverdose\/data\/analysis.html; accessed 22 May 2018"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0004","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1517\/13543780902751622","article-title":"Opioid formulations in development designed to curtail abuse: who is the target?","volume":"18","author":"Webster","year":"2009","journal-title":"Expert opinion on investigational drugs"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1477-7517-6-8","article-title":"Can abuse deterrent formulations make a difference? Expectation and speculation","volume":"6","author":"Budman","year":"2009","journal-title":"Harm reduction journal"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0006","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/00952990.2011.569623","article-title":"Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions","volume":"37","author":"Katz","year":"2011","journal-title":"The American journal of drug and alcohol abuse"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0007","unstructured":"US Food and Drug Administration. Guidance for Industry: Abuse-Deterrent Opioids\u2014Evaluation and Labeling. 2015. https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM334743.pdf; accessed 22 May 2018"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0008","first-page":"38","article-title":"Abuse-resistant, extended-release morphine is resistant to physical manipulation techniques commonly used by opioid abusers","volume":"126","author":"DiFalco","year":"2014","journal-title":"Postgraduate medicine"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0009","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.jpain.2014.01.315","article-title":"Extraction testing of a novel extended-release, abuse-deterrent formulation of morphine, Morphine ARER, in common solvents","volume":"15","author":"Bianchi","year":"2014","journal-title":"Journal of pain"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0010","first-page":"58","article-title":"In vitro evaluation of Morphine ARER potential for abuse via injection","volume":"126","author":"Kinzler","year":"2014","journal-title":"Postgraduate medicine"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0011","first-page":"1303","article-title":"A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine-Morphine ARER","volume":"18","author":"Webster","year":"2017","journal-title":"Pain medicine"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0012","unstructured":"Centers for Disease Control and Prevention. CDC Vital Signs: Opioid Painkiller Prescribing. 2014. https:\/\/www.cdc.gov\/vitalsigns\/opioid-prescribing\/index.html; Access 22 May 2018"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0013","unstructured":"Center for Lawful Access and Abuse Deterrence. National Prescription Drug Abuse Prevention Strategy: 2015 Update. http:\/\/claad.org\/wp-content\/uploads\/2015\/05\/NS-2015-Update1.pdf; accessed 22 May 2018"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0014","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.drugalcdep.2017.01.039","article-title":"Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration","volume":"175","author":"Green","year":"2017","journal-title":"Drug and alcohol dependence"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11926-008-0003-z","article-title":"Abuse-deterrent opioid formulations: are they a pipe dream?","volume":"10","author":"Katz","year":"2008","journal-title":"Current rheumatology reports"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0016","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/00000542-199710000-00008","article-title":"Opioid-induced delay in gastric emptying: a peripheral mechanism in humans","volume":"87","author":"Murphy","year":"1997","journal-title":"Anesthesiology"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0017","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jpain.2012.08.008","article-title":"Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment","volume":"14","author":"Butler","year":"2013","journal-title":"Journal of pain"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0018","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/cpt.390","article-title":"The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting","volume":"100","author":"Coplan","year":"2016","journal-title":"Clinical pharmacology and therapeutics"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0019","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.drugalcdep.2016.09.018","article-title":"Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone","volume":"168","author":"Severtson","year":"2016","journal-title":"Drug and alcohol dependence"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0020","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/jcph.235","article-title":"Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users","volume":"54","author":"Harris","year":"2014","journal-title":"Journal of clinical pharmacology"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0021","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1155\/2013\/952082","article-title":"Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users","volume":"18","author":"Setnik","year":"2013","journal-title":"Pain research and management"},{"key":"10.1016\/j.clinthera.2018.06.010_bib0022","first-page":"1695","article-title":"Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users","volume":"18","author":"Webster","year":"2017","journal-title":"Pain medicine"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818302613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818302613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:43Z","timestamp":1758962983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818302613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0149291818302613"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.06.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}